PLGA nanoparticles co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T cell and B cell responses
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F21%3A00541770" target="_blank" >RIV/61389013:_____/21:00541770 - isvavai.cz</a>
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2021.641703/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fimmu.2021.641703/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2021.641703" target="_blank" >10.3389/fimmu.2021.641703</a>
Alternative languages
Result language
angličtina
Original language name
PLGA nanoparticles co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T cell and B cell responses
Original language description
Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunotherapy. Here, we developed a PLGA-based nanoparticle vaccine that contains both the immunogenic cancer germline antigen NY-ESO-1 and an α-GalCer analog IMM60, as a novel iNKT cell agonist and dendritic cell transactivator. Three peptide sequences (85–111, 117–143, and 157–165) derived from immunodominant regions of NY-ESO-1 were selected. These peptides have a wide HLA coverage and were efficiently processed and presented by dendritic cells via various HLA subtypes. Co-delivery of IMM60 enhanced CD4 and CD8 T cell responses and antibody levels against NY-ESO-1 in vivo. Moreover, the nanoparticles have negligible systemic toxicity in high doses, and they could be produced according to GMP guidelines. Together, we demonstrated the feasibility of producing a PLGA-based nanovaccine containing immunogenic peptides and an iNKT cell agonist, that is activating DCs to induce antigen-specific T cell responses.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10404 - Polymer science
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Immunology
ISSN
1664-3224
e-ISSN
1664-3224
Volume of the periodical
12
Issue of the periodical within the volume
February
Country of publishing house
CH - SWITZERLAND
Number of pages
15
Pages from-to
641703
UT code for WoS article
000627356500001
EID of the result in the Scopus database
2-s2.0-85102439124